Successful Readout Of Prospective Phase 2 Sinergy Trial Supports Signateratm Mrd-Guided Treatment
Feb 24 (Reuters) - Natera Inc NTRA.O:
SUCCESSFUL READOUT OF PROSPECTIVE PHASE 2 SINERGY TRIAL SUPPORTS SIGNATERATM MRD-GUIDED TREATMENT IN HEAD AND NECK CANCER
NATERA INC - TRIAL ACHIEVES 63% RESPONSE RATE, REDUCES CHEMOTHERAPY IN 74% OF PATIENTS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.